X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IM-3050, the company’s Preclinical lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein, is being investigated for the treatment of cancer indications.
Lead Product(s): IM-3050
Therapeutic Area: Oncology Product Name: IM-3050
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
Through the acquisition, Immunome have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors, and related drug candidate AL101 from Ayala.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Ayala Pharmaceuticals
Deal Size: $87.5 million Upfront Cash: $20.0 million
Deal Type: Acquisition March 26, 2024
Details:
The net proceeds will be allocated towards the development of IM-1021, a topoisomerase I inhibitor currently under evaluation for the treatment of patients afflicted with triple-negative cancer.
Lead Product(s): IM-1021
Therapeutic Area: Oncology Product Name: IM-1021
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2024
Details:
The net proceeds will be allocated towards the development of IM-1021, a topoisomerase I inhibitor currently under evaluation for the treatment of patients afflicted with triple-negative cancer.
Lead Product(s): IM-1021
Therapeutic Area: Oncology Product Name: IM-1021
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
Through the acquisition, Immunome will have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors, and related drug candidate AL101 from Ayala.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Ayala Pharmaceuticals
Deal Size: $87.5 million Upfront Cash: $20.0 million
Deal Type: Acquisition February 06, 2024
Details:
Under the agreement, Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
Lead Product(s): ZPC-21
Therapeutic Area: Oncology Product Name: ZPC-21
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Zentalis Pharmaceuticals
Deal Size: $310.0 million Upfront Cash: $35.0 million
Deal Type: Licensing Agreement January 08, 2024
Details:
Through the acquisition, Immunome aims to utilize Atreca's APN-497444, a Glycan receptor inhibitor currently in the discovery stage, for the treatment of gastrointestinal cancers.
Lead Product(s): APN-497444
Therapeutic Area: Oncology Product Name: APN-497444
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Atreca
Deal Size: $12.5 million Upfront Cash: $5.5 million
Deal Type: Acquisition December 26, 2023
Details:
The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Morphimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 03, 2023
Details:
The net proceeds will be used to continue development of the lead assets in Immunome’s combined pipeline including, IMM20320, a novel anti-IL-38 mAb, and to continue to advance the company’s platforms.
Lead Product(s): IMM20320
Therapeutic Area: Oncology Product Name: IMM20320
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Enavate Sciences
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 03, 2023
Details:
The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Morphimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
